CLINICAL TRIALS PROFILE FOR BRILLIANT BLUE G
✉ Email this page to a colleague
All Clinical Trials for Brilliant Blue G
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00738413 ↗ | Iron Balance Study of Deferasirox, Deferoxamine and the Combination of Both | Unknown status | Weill Medical College of Cornell University | Phase 1/Phase 2 | 2008-08-01 | Subjects with thalassemia major require regular transfusion therapy to sustain life. The iron present in the transfused blood remains in the body where it can cause a variety of organ dysfunctions. Lifelong iron chelation therapy is needed to maintain iron balance but its effectiveness varies greatly. Like that of deferoxamine (Desferal, DFO) the mainstay of chelation therapy for 30 years, the effectiveness of deferasirox (Exjade, ICL670), the newly approved, orally effective iron chelating drug, is not satisfactory in all subjects. Even with good compliance, the iron excretion induced by a given drug exhibits wide subject-to-subject variability. There is often persistent iron overload of extra hepatic tissues such as the heart and pancreas leading to cardiac disease and diabetes. Combining the drugs may be a better approach in those subjects at increased risk. The iron balance studies proposed will permit an assessment of the potential of such a combination to place subjects in net negative iron balance and the relative effectiveness of the combination in relation to that of the individual drugs, an additive effect being expected. With such information, physicians will be able to design individualized chelation regimens that maximize effectiveness while minimizing side effects by adjusting the ratio and/or the dosing schedule of the two drugs. |
| NCT01718314 ↗ | Comparison of Sublingual Misoprostol Versus Lidocaine Spray for Hysteroscopy | Completed | Dr. Sami Ulus Children's Hospital | N/A | 2008-03-01 | Hysteroscopy is an instrument to visualize the interior walls of uterus (womb) and it enables the doctor to do minor operative procedures. Although it causes little discomfort, sometimes it may be disturbing for the patient. This pain is usually perceived during the passage of the instrument through the cervix (neck of the womb). The investigators would like to minimize this pain by two drugs: Misoprotol and lidocaine |
| NCT01820520 ↗ | Safety and Efficacy of Double Staining With Brilliant Blue G for Macular Surgery | Unknown status | Asociación para Evitar la Ceguera en México | Phase 3 | 2013-01-01 | Study designed to evaluate the safety and efficacy of double staining with brilliant blue G 0.025% as an adjuvant to macular surgery. Patients undergoing surgery for macular hole or epiretinal membrane will be included. Safety will be evaluated by optic coherence tomography, pattern reversal electroretinogram and multifocal electroretinogram. |
| NCT02052219 ↗ | BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy | Withdrawn | Anthera Pharmaceuticals | Phase 3 | 2014-10-01 | The purpose of this study is to compare the effect of blisibimod plus standard of care versus placebo plus standard of care alone on the proportion of subjects achieving improvement in renal disease parameters. |
| NCT03020459 ↗ | Internal Limiting Membrane Peeling-reposition to Treat Idiopathic Macular Holes | Completed | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | N/A | 2017-01-01 | To compare the morphologic and functional outcomes of internal limiting membrane peeling-reposition versus peeling in idiopathic macular holes |
| NCT03214406 ↗ | Clinical Evaluation of the Efficacy of a Marketed Dentifrice on Plaque and Gingivitis | Completed | Church & Dwight Company, Inc. | N/A | 2010-02-08 | Parallel, double blind, randomized, Institutional Review Board (IRB) -approved study involving approximately 160 subjects to complete. Subjects were randomly assigned to either the test product (Arm & Hammer Advance White Brilliant Sparkle) or the control (Crest Cavity Protection Regular) based on baseline mean whole-mouth plaque and gingival scores and age.Subjects brushed with their assigned dentifrice two times (2X) daily and were evaluated for gingivitis, bleeding and plaque at Baseline and after 4-, 8-, and 12-weeks of product use. Return to pre-study hygiene regimen for 4 weeks and final evaluation at 16 weeks. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Brilliant Blue G
Condition Name
Clinical Trial Locations for Brilliant Blue G
Trials by Country
Clinical Trial Progress for Brilliant Blue G
Clinical Trial Phase
Clinical Trial Sponsors for Brilliant Blue G
Sponsor Name
